Clinical Report: The Case for Early Action in Geographic Atrophy (GA)

Overview

A recent survey reveals that patients with geographic atrophy (GA) recognize the importance of early treatment to preserve vision. The findings highlight the psychological burden of GA and the willingness of patients to adhere to treatment despite uncertainties.

Background

Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to irreversible vision loss. Understanding patient perspectives on treatment is crucial, as it can inform clinical practices and improve patient outcomes. The emotional and psychological impacts of GA are significant, necessitating a holistic approach to management.

Data Highlights

No numerical data available in the article.

Key Findings

• 98% of surveyed GA patients report that the disease impacts their mental health.
• 92% experience stress or anxiety due to uncertainty about future vision loss.
• 95% of patients receiving treatment are willing to adhere to ongoing appointments to preserve vision.
• 90% of treated patients report a more positive outlook on life since starting treatment.
• 89% feel that treatment helps ease their worries about the future.

Clinical Implications

Clinicians should engage in early, evidence-based discussions with GA patients about treatment options and the potential benefits of early intervention. Addressing the psychological aspects of GA can enhance patient compliance and overall well-being.

Conclusion

The survey underscores the importance of early action in managing geographic atrophy, highlighting both the clinical and emotional benefits of timely treatment. Empowering patients through education and partnership can lead to better outcomes.

References

1. Optometric Management, 2025 -- Importance of Early Identification of Geographic Atrophy and Treatment Recommendations
2. Ophthalmology Management, 2026 -- Case Study: Early Treatment of Geographic Atrophy
3. Optometric Management, 2025 -- Geographic Atrophy: Early Detection and Patient Awareness Matters
4. Oregon Health & Science University -- Age-Related Macular Degeneration Preferred Practice Pattern®
5. ScienceDirect -- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY)
6. optometric management — Detecting Diagnostic and Prognostic Biomarkers of Geographic Atrophy
7. Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
8. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials - ScienceDirect
9. Visual Acuity and Quality of Life Outcomes With Pegcetacoplan Treatment: A Post Hoc Analysis From the OAKS and DERBY Trials - PubMed